

North Central Cancer Treatment Group

N0177: A Phase I/II Trial of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Status Change – July 11, 2006

NOTICE OF STATUS CHANGE

Study 2 is temporarily suspended to EIAC patients effective immediately, **Tuesday, July 11, 2006 at 4:30 CST** as accrual to dose level 2E (450 mg OSI-774) has been met.

Please retain this notice with the protocol.